In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement

Ítems similars

• Response to “In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement”
  per: Iwahori, Kota, et al.
  Publicat: (2015)
• Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
  per: Blanco, Belén, et al.
  Publicat: (2020)
• Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
  per: Compte, Marta, et al.
  Publicat: (2014)
• Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager
  per: Marina Gómez-Rosel, et al.
  Publicat: (2025-12-01)
• Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
  per: Zhong, Liping, et al.
  Publicat: (2021)